Literature DB >> 22278243

Correlation of recombinant integrase activity and functional preintegration complex formation during acute infection by replication-defective integrase mutant human immunodeficiency virus.

Xiang Li1, Yasuhiro Koh, Alan Engelman.   

Abstract

Previous studies characterized two types of replication-defective human immunodeficiency virus type 1 (HIV-1) integrase mutants: class I, which are specifically blocked at the integration step, and class II, which harbor additional virion production and/or reverse transcription defects. Class I mutant enzymes supported little if any metal ion-dependent 3'-processing and DNA strand transfer activities in vitro, whereas class II enzymes displayed partial or full catalytic function in studies with simplified assay designs, suggesting that defective interaction(s) with heterologous integrase binding proteins might underlie the class II mutant viral phenotype. To address this hypothesis, class I and II mutant enzymes were interrogated under expanded sets of in vitro conditions. The majority failed to catalyze the concerted integration of two viral DNA ends into target DNA, highlighting defective integrase function as the root cause of most class II in addition to all class I mutant virus infection defects. One mutant protein, K264E, in contrast, could support the wild-type level of concerted integration activity. After accounting for its inherent reverse transcription defect, HIV-1(K264E) moreover formed preintegration complexes that supported the efficient integration of endogenous viral DNA in vitro and normal levels and sequences of 2-long terminal repeat-containing circle junctions during acute infection. K264E integrase furthermore efficiently interacted in vitro with two heterologous binding partners, LEDGF/p75 and reverse transcriptase. Our results underscore the physiological relevance of concerted integration assays for tests of integrase mutant function and suggest that the K264E mutation disrupts an interaction with an intranuclear integrase binding partner that is important for HIV-1 integration.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22278243      PMCID: PMC3302524          DOI: 10.1128/JVI.06386-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  127 in total

1.  Two bases are deleted from the termini of HIV-1 linear DNA during integrative recombination.

Authors:  C D Pauza
Journal:  Virology       Date:  1990-12       Impact factor: 3.616

2.  Retroviral integration: structure of the initial covalent product and its precursor, and a role for the viral IN protein.

Authors:  P O Brown; B Bowerman; H E Varmus; J M Bishop
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

3.  Correct integration of retroviral DNA in vitro.

Authors:  P O Brown; B Bowerman; H E Varmus; J M Bishop
Journal:  Cell       Date:  1987-05-08       Impact factor: 41.582

4.  Integration of human immunodeficiency virus type 1 DNA in vitro.

Authors:  C M Farnet; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

5.  A nucleoprotein complex mediates the integration of retroviral DNA.

Authors:  B Bowerman; P O Brown; J M Bishop; H E Varmus
Journal:  Genes Dev       Date:  1989-04       Impact factor: 11.361

6.  Integration is not necessary for expression of human immunodeficiency virus type 1 protein products.

Authors:  M Stevenson; S Haggerty; C A Lamonica; C M Meier; S K Welch; A J Wasiak
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

7.  Activities of human immunodeficiency virus (HIV) integration protein in vitro: specific cleavage and integration of HIV DNA.

Authors:  F D Bushman; R Craigie
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

8.  Evaluation of the functional involvement of human immunodeficiency virus type 1 integrase in nuclear import of viral cDNA during acute infection.

Authors:  Tamako Ikeda; Hironori Nishitsuji; Xin Zhou; Nobuo Nara; Takashi Ohashi; Mari Kannagi; Takao Masuda
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

9.  Characterization of human immunodeficiency virus type 1 Pr160 gag-pol mutants with truncations downstream of the protease domain.

Authors:  Wei-Hao Liao; Chin-Tien Wang
Journal:  Virology       Date:  2004-11-10       Impact factor: 3.616

10.  Retroviral DNA integration: structure of an integration intermediate.

Authors:  T Fujiwara; K Mizuuchi
Journal:  Cell       Date:  1988-08-12       Impact factor: 41.582

View more
  16 in total

1.  Multimode, cooperative mechanism of action of allosteric HIV-1 integrase inhibitors.

Authors:  Jacques J Kessl; Nivedita Jena; Yasuhiro Koh; Humeyra Taskent-Sezgin; Alison Slaughter; Lei Feng; Suresh de Silva; Li Wu; Stuart F J Le Grice; Alan Engelman; James R Fuchs; Mamuka Kvaratskhelia
Journal:  J Biol Chem       Date:  2012-03-21       Impact factor: 5.157

2.  Interaction between Reverse Transcriptase and Integrase Is Required for Reverse Transcription during HIV-1 Replication.

Authors:  Shewit S Tekeste; Thomas A Wilkinson; Ethan M Weiner; Xiaowen Xu; Jennifer T Miller; Stuart F J Le Grice; Robert T Clubb; Samson A Chow
Journal:  J Virol       Date:  2015-09-23       Impact factor: 5.103

Review 3.  HIV integrase inhibitors: 20-year landmark and challenges.

Authors:  Mathieu Métifiot; Christophe Marchand; Yves Pommier
Journal:  Adv Pharmacol       Date:  2013

4.  The HIV-1 integrase mutant R263A/K264A is 2-fold defective for TRN-SR2 binding and viral nuclear import.

Authors:  Stéphanie De Houwer; Jonas Demeulemeester; Wannes Thys; Susana Rocha; Lieve Dirix; Rik Gijsbers; Frauke Christ; Zeger Debyser
Journal:  J Biol Chem       Date:  2014-07-25       Impact factor: 5.157

5.  Interaction of the HIV-1 intasome with transportin 3 protein (TNPO3 or TRN-SR2).

Authors:  Ross Larue; Kushol Gupta; Christiane Wuensch; Nikolozi Shkriabai; Jacques J Kessl; Eric Danhart; Lei Feng; Oliver Taltynov; Frauke Christ; Gregory D Van Duyne; Zeger Debyser; Mark P Foster; Mamuka Kvaratskhelia
Journal:  J Biol Chem       Date:  2012-08-07       Impact factor: 5.157

6.  Biochemical characterization of novel retroviral integrase proteins.

Authors:  Allison Ballandras-Colas; Hema Naraharisetty; Xiang Li; Erik Serrao; Alan Engelman
Journal:  PLoS One       Date:  2013-10-04       Impact factor: 3.240

7.  Identification of low molecular weight nuclear complexes containing integrase during the early stages of HIV-1 infection.

Authors:  Annabelle Gérard; Nicolas Soler; Emmanuel Ségéral; Michael Belshan; Stéphane Emiliani
Journal:  Retrovirology       Date:  2013-02-01       Impact factor: 4.602

8.  HRP2 determines the efficiency and specificity of HIV-1 integration in LEDGF/p75 knockout cells but does not contribute to the antiviral activity of a potent LEDGF/p75-binding site integrase inhibitor.

Authors:  Hao Wang; Kellie A Jurado; Xiaolin Wu; Ming-Chieh Shun; Xiang Li; Andrea L Ferris; Steven J Smith; Pratiq A Patel; James R Fuchs; Peter Cherepanov; Mamuka Kvaratskhelia; Stephen H Hughes; Alan Engelman
Journal:  Nucleic Acids Res       Date:  2012-10-05       Impact factor: 16.971

9.  Nucleoporin NUP153 phenylalanine-glycine motifs engage a common binding pocket within the HIV-1 capsid protein to mediate lentiviral infectivity.

Authors:  Kenneth A Matreyek; Sara S Yücel; Xiang Li; Alan Engelman
Journal:  PLoS Pathog       Date:  2013-10-10       Impact factor: 6.823

10.  Integrase residues that determine nucleotide preferences at sites of HIV-1 integration: implications for the mechanism of target DNA binding.

Authors:  Erik Serrao; Lavanya Krishnan; Ming-Chieh Shun; Xiang Li; Peter Cherepanov; Alan Engelman; Goedele N Maertens
Journal:  Nucleic Acids Res       Date:  2014-02-11       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.